Pulmonary Surfactant Nanoparticles for Lung‐Targeted and Dose‐Efficient Delivery
Advanced Healthcare Materials · 2026-06 · 15 (24)
DOI: 10.1002/adhm.202505871 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 19.05.2026. Verfasst von Laura Fernández-Méndez und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia, Spain. Hauptthemen laut MEDLINE: Nanoparticles, Lung, Pulmonary Surfactants, Drug Delivery Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Ramón Areces Foundation, MCIN/AEI 10.13039/501100011033 projects, Basque Government projects.
Abstract (Originalsprache)
Although pulmonary drug delivery enables lung‐targeted therapy, its clinical efficacy is often limited by inflammation, heterogeneous deposition, and physiological barriers such as mucociliary clearance and phagocytic uptake. Here, we report a biomimetic platform based on pulmonary surfactant nanoparticles (PS NPs ) that preserves native surfactant proteins and biophysical functionality, resulting in enhanced pulmonary delivery. Microfluidic synthesis yielded highly uniform PS NPs with improved encapsulation efficiency and colloidal stability, while markedly increasing surfactant protein retention from 33% using conventional extrusion to 95% via microfluidics, corresponding to a 2.4‐fold improvement. Functionally, PS NPs exhibited superior interfacial activity compared to lipid‐only liposomes, increasing surface pressure from 5–10 mN/m to 25–30 mN/m, and achieved an approximately 80‐fold enhancement in alveolar cellular uptake. In vitro, nintedanib‐loaded PS NPs significantly reduced fibroblast migration, proliferation, collagen deposition, and TGF‐β secretion relative to free drug and control formulations. In vivo, PS NPs demonstrated high pulmonary retention (95% injected dose per gram of lung tissue), efficient penetration into fibrotic regions, and minimal off‐target accumulation in the liver (0.5%). Therapeutic efficacy was confirmed in a bleomycin‐induced pulmonary fibrosis model, where PS NPs improved lung function and restored tissue architecture at doses as low as 0.5 mg/kg. Collectively, these results establish PS NPs as a robust lung‐targeted nanotherapeutic platform, where microfluidic synthesis enables enhanced biomimicry, improved protein preservation, and superior therapeutic performance compared to conventional fabrication methods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia, Spain.
- Euskal Herriko Unibertsitatea (EHU), Donostia, Spain.
- CIBER of Respiratory Diseases (CIBERES), Madrid, Spain.
- Proteomics Platform CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Science and Technology Park, CIBERehd, Derio, Spain.
- Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Universidad Complutense de Madrid, Madrid, Spain.
- GENYO-Center for Genomics and Oncological Research, Pfizer/University of Granada/ Junta de Andalucía and Department of Cell Biology, School of Sciences, University of Granada, Granada, Spain.
ORCID-Profile: Laura Fernández-Méndez, Claudia Miranda-Pérez de Alejo, Susana Carregal-Romero
Förderung
- Ramón Areces Foundation
- MCIN/AEI 10.13039/501100011033 projects
- Basque Government projects
- Gipuzkoa Provincial Council
- MCIN/AEI/10.13039/501100011033
- Basque Government
- R&D projects in Health
- Ramón y Cajal Program
Zitieren
APA
Fernández-Méndez, L., Piñol-Cancer, M., Souto-Riobó, I., Urkola-Arsuaga, A., González-Lozano, E., Fernández-Folgueral, I., de Alejo, C. M., Azkargorta, M., Elortza, F., Tagliaferro-Quiñonero, A., Silvio, D. D., Cañadas, O., Maiz, J., Pérez-Gil, J., Ramos-Cabrer, P., Ruíz-Cabello, J., & Carregal-Romero, S. (2026). Pulmonary Surfactant Nanoparticles for Lung‐Targeted and Dose‐Efficient Delivery. Advanced Healthcare Materials, 15(24). https://doi.org/10.1002/adhm.202505871
Vancouver
Fernández-Méndez L, Piñol-Cancer M, Souto-Riobó I, Urkola-Arsuaga A, González-Lozano E, Fernández-Folgueral I, et al. Pulmonary Surfactant Nanoparticles for Lung‐Targeted and Dose‐Efficient Delivery. Advanced Healthcare Materials. 2026;15(24). doi:10.1002/adhm.202505871
BibTeX
@article{FernndezMndez2026,
author = {Fernández-Méndez, Laura and Piñol-Cancer, Marina and Souto-Riobó, Itziar and Urkola-Arsuaga, Ainhize and González-Lozano, Elena and Fernández-Folgueral, Irene and de Alejo, Claudia Miranda-Pérez and Azkargorta, Mikel and Elortza, Felix and Tagliaferro-Quiñonero, Alberto and Silvio, Desire Di and Cañadas, Olga and Maiz, Jon and Pérez-Gil, Jesús and Ramos-Cabrer, Pedro and Ruíz-Cabello, Jesús and Carregal-Romero, Susana},
title = {Pulmonary Surfactant Nanoparticles for Lung‐Targeted and Dose‐Efficient Delivery},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {24},
doi = {10.1002/adhm.202505871}
}
EUVIMED